Aquestive's Liluazole oral membrane agent Exservan received FDA approval a week in advance
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Aquestive Therapeutics(http:// announcedthat its development of the Liluzole oral membrane agent Exservan was approved by the U.SFDA(http://a week ahead of schedule, for the treatment of patients with amyotrophic lateral sclerosis (ALS)About Exservan
Exservan is a liluzole, the first FDA-approveddrug to treat ALS
(http://, tabletproduct(http://was introduced in 1995 to delay patients' respiratory dependenceTo date, four drugs have been approved by the FDA for the treatment of ALS, three of which are Liroudine products of different dosage forms: Exservan (Liluzole oral membrane agent), Rilutek (Lilua tablet), Tiglutik (Lilua leachium, Radicava (edaravone, Idala intravenous fluid)Radicava, from Mitsubishi Tianbian, was approved by the FDA in 2017 and is the first new drug (http:// approved by the agency in the past 22 years Radicava's active pharmaceutical ingredient, edaravone , is a free radical scavenger that is thought to relieve the effects of oxidative stress, which may be a key factor in the onset and development of ALS The antioxidant effect sedaravone is thought to provide nerve protective support to the nervous system, potentially delaying disease development or limiting additional damage In China, Radicava was approved by the National Medicines (http:// Regulatory Authority (NMPA) at the end of July
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
